DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Regulation FD Disclosure

0

DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

A copy of the presentation materials that will be used by Depomed,Inc. (the “Company”) in meetings with the investment community on February14, 2018 in New York, New York is attached as Exhibit99.1 to this Form8-K and is incorporated by reference to this Item 7.01. A copy of the Company’s presentation materials has also been posted to the Company’s website.

This information is being furnished to Item 7.01 of this Current Report on Form8-K and shall not be deemed to be “filed” for the purposes of Section18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Current Report on Form8-K will not be deemed an admission as to the materiality of any information in this Current Report on Form8-K that is being disclosed to Regulation FD.


DEPOMED INC Exhibit
EX-99.1 2 a18-6001_1ex99d1.htm EX-99.1 Exhibit 99.1 LEERINK Partners 7th Annual Global Healthcare Conference February 14,…
To view the full exhibit click here

About DEPOMED,INC. (NASDAQ:DEPO)

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company’s products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.

An ad to help with our costs